KR20170046146A - 각막 동종이식 거부 및 신혈관 형성의 예방을 위한 글루코 코르티코이드-로딩된 나노입자 - Google Patents

각막 동종이식 거부 및 신혈관 형성의 예방을 위한 글루코 코르티코이드-로딩된 나노입자 Download PDF

Info

Publication number
KR20170046146A
KR20170046146A KR1020177006811A KR20177006811A KR20170046146A KR 20170046146 A KR20170046146 A KR 20170046146A KR 1020177006811 A KR1020177006811 A KR 1020177006811A KR 20177006811 A KR20177006811 A KR 20177006811A KR 20170046146 A KR20170046146 A KR 20170046146A
Authority
KR
South Korea
Prior art keywords
dsp
injection
polymer
nanoparticles
glucocorticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177006811A
Other languages
English (en)
Korean (ko)
Inventor
저스틴 스캇 헤인즈
칭 판
칭구오 쉬
니콜라스 제이. 보이랜
월터 제이. 스타크
빙 왕
리샤 루오
Original Assignee
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티 filed Critical 더 존스 홉킨스 유니버시티
Publication of KR20170046146A publication Critical patent/KR20170046146A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
KR1020177006811A 2014-08-13 2015-08-03 각막 동종이식 거부 및 신혈관 형성의 예방을 위한 글루코 코르티코이드-로딩된 나노입자 Withdrawn KR20170046146A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462037000P 2014-08-13 2014-08-13
US62/037,000 2014-08-13
US201562139561P 2015-03-27 2015-03-27
US62/139,561 2015-03-27
PCT/US2015/043478 WO2016025215A1 (en) 2014-08-13 2015-08-03 Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization

Publications (1)

Publication Number Publication Date
KR20170046146A true KR20170046146A (ko) 2017-04-28

Family

ID=54011072

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177006811A Withdrawn KR20170046146A (ko) 2014-08-13 2015-08-03 각막 동종이식 거부 및 신혈관 형성의 예방을 위한 글루코 코르티코이드-로딩된 나노입자

Country Status (8)

Country Link
US (1) US10195212B2 (enExample)
EP (1) EP3193827A1 (enExample)
JP (1) JP2017524712A (enExample)
KR (1) KR20170046146A (enExample)
CN (1) CN106794152A (enExample)
CA (1) CA2957764C (enExample)
MX (1) MX2017001863A (enExample)
WO (1) WO2016025215A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
KR20170094793A (ko) 2014-12-15 2017-08-21 더 존스 홉킨스 유니버시티 수니티닙 제제 및 녹내장의 치료에서의 그의 사용 방법
WO2016100086A1 (en) 2014-12-15 2016-06-23 The Johns Hopkins University Cvs transplantation for treatment of bacterial vaginosis
US10485757B2 (en) 2015-01-27 2019-11-26 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
MX2018005932A (es) 2015-11-12 2019-05-20 Graybug Vision Inc Microparticulas aglomerantes para terapia medica.
DE102017002454A1 (de) * 2017-03-14 2018-09-20 Friedrich-Schiller-Universität Jena Organische Polymerpartikel enthaltend Poly(oxazolin)-Stabilisatoren und Verwendung von Poly(oxazolinen) zur Stabilisierung von organischen Polymerpartikeln
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
WO2019071275A1 (en) * 2017-10-06 2019-04-11 Aciont Inc. DEVICES FOR DELIVERY OF NON-INVASIVE OCULAR MEDICINE
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
US20230081539A1 (en) * 2020-02-21 2023-03-16 The Johns Hopkins University Suprachoroidal delivery of drug particles to reduce toxicity

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4888176A (en) 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO2004084871A1 (en) * 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targenting drug delivery and sustained drug release
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20050226814A1 (en) 2004-04-13 2005-10-13 Bausch & Lomb Incorporated Diagnostic method and kit for implantation of a sustained release drug-delivery implant with a steroid
US20060089590A1 (en) * 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
JP2007001926A (ja) * 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
US8916206B2 (en) * 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
EP2156848A4 (en) * 2007-05-14 2012-11-28 Ltt Bio Pharma Co Ltd NANOPARTICLE CONTAINING A LOW MOLECULAR WEIGHT DRUG HAVING A NEGATIVELY PROLONGED RELEASE GROUP
CN101970042A (zh) * 2008-02-25 2011-02-09 眼门药品公司 经由离子电渗法增强递送治疗药物至眼部组织
US20110206773A1 (en) 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
EP2482818A4 (en) 2009-09-29 2014-04-09 Eyegate Pharmaceuticals Inc POSITIVELY CHARGED POLY (D, L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES AND METHODS OF MAKING SAME
WO2013038195A2 (en) 2011-09-13 2013-03-21 Altacor Limited Pharmaceutical nanoparticle compositions
RU2598627C2 (ru) * 2012-01-19 2016-09-27 Дзе Джонс Хопкинс Юниверсити Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки
KR20150006869A (ko) * 2012-05-03 2015-01-19 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자

Also Published As

Publication number Publication date
US10195212B2 (en) 2019-02-05
CA2957764A1 (en) 2016-02-18
MX2017001863A (es) 2017-07-17
CA2957764C (en) 2019-07-02
US20170157147A1 (en) 2017-06-08
JP2017524712A (ja) 2017-08-31
CN106794152A (zh) 2017-05-31
WO2016025215A1 (en) 2016-02-18
EP3193827A1 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
US10195212B2 (en) Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization
US11660349B2 (en) Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
JP6570513B2 (ja) 持続的眼内放出のためのマイクロスフェア薬剤送達システム
Liu et al. Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage
EP3233056B1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
US20100204325A1 (en) Valproic acid drug delivery systems and intraocular therapeutic uses thereof
CN104363924A (zh) 用于递送hif-1抑制剂的控制释放调配物
JP2015013863A (ja) 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
KR20210013339A (ko) 개선된 점막 수송을 나타내는 제약 나노입자
JP2018515529A (ja) ハイドロゲルからの薬物送達
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
US20250009755A1 (en) Compositions and methods for the treatment of ocular diseases and injuries
US11369575B2 (en) PPARα agonist compositions and methods of use
Kundu et al. Emerging drug delivery strategies for glaucoma therapy: focus on nanoparticles and stimuli-responsive systems
CN119947711A (zh) 用于持续药物递送的有机凝胶、其制备方法和用途
Pillay et al. Intraocular drug delivery technologies: advancing treatment of posterior segment disorders of the eye
US20190022016A1 (en) Compositions for sustained release of anti-glaucoma agents to control intraocular pressure
JP2024534403A (ja) 眼疾患のための緑茶ベースのナノコンプレックス
Ramesh Ocular barriers and ocular drug delivery: Bridging the gap using nanomicelles as drug carriers
Schmitt Design and development of ocular formulations for preclinical and clinical trials
Genov et al. Innovative drug delivery in ophthalmology
Virmani et al. Eyes on the Future: Nano-medicine Innovations in Enhancing Ocular Bioavailability
Chowdhury Development and preliminary in vitro evaluation of nanomicelles laden in situ gel of dexamethasone for ophthalmic delivery
HK1241281A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
HK1241281B (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170310

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination